Trial
NCT04442581
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Exelixis
Condition
Advanced Hepatocellular Carcinoma
Intervention
Cabozantinib S-malate
Why stopped
Terminated due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-05